Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic ...

The FDA approved vorasidenib (Voranigo) for patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation. The drug -- an IDH1 and IDH2 inhibitor - ...

In August 2024, the FDA approved six new cancer treatments, including some that haven’t previously been approved. During the summer of 2024, the Food and Drug Administration (FDA) approved a handful ...

The FDA has approved Voranigo to treat certain patients with grade 2 astrocytoma or oligodendroglioma with select mutations, following surgery. The Food and Drug Administration (FDA) has approved ...

The Nature Index 2024 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Picture a film editor piecing together a blockbuster. Each scene must flow seamlessly to tell the story. In our cells, RNA plays that script editing role, splicing together genetic “scenes” so ...

Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic mutations – IDH2 and SRSF2 – work cooperatively to mis-splice RNA messages ...